Rise of the Polypill
Renewed calls for polypills come after studies showed its value in preventive medicine.
Medicine Needs Civil Disobedience
Controlled, willful acts of resistance have been a powerful agent of change throughout history. We need it in medicine, now...
Emerson Fought the Materialists
Ralph Waldo Emerson defined the humanist origins of medicine. We praise his work, but we forget he fought against the...
Can Medicine Return to its Roots?
We built modern medicine on data. They provide certainty when facing the unknown. But the heart of medicine is uncertainty....
Stop Calling Medicine a Right
We should question why we look at medicine as a right. It is a legal concept that cannot address uncertainty...
Empathy Gaps, Moral Hazards
Medicine has become a vast system. As it grew, we lost empathy for patients and replaced it with a nexus...
Medicine is a Duty, Not a Right
Rights force us to think individually. But medicine is a duty. It works only when we think of service to...
Healthcare Has Always Been Political
Recent political tensions have put a strain on healthcare. This is nothing new. Throughout history, politics have influenced healthcare and...
Hearing Aids for the Masses
Select over the counter hearing aids will be available soon. The move aims to lower costs. Instead, it will reveal...
History of Medical Jurisprudence
We delve into the woefully understudied discipline and glean the perspective of the physician luminary, Dr. William Osler.
Will Drug Prices Actually Fall?
The Inflation Reduction Act promises to reduce drug prices. But the law is more financial gamesmanship than true patient advocacy,...
I joined an abortion clinic protest
We spoke with protesters outside of an abortion clinic to understand their position on abortion and their purpose for protesting....
Videos
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more